NASDAQ:ARVN Arvinas (ARVN) Stock Price, News & Analysis $24.40 -0.55 (-2.20%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$23.75▼$25.1750-Day Range$23.81▼$32.7352-Week Range$13.57▼$53.08Volume404,105 shsAverage Volume761,916 shsMarket Capitalization$1.67 billionP/E RatioN/ADividend YieldN/APrice Target$57.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arvinas alerts: Email Address Arvinas MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside135.7% Upside$57.50 Price TargetShort InterestBearish17.46% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.32Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.51) to ($4.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.03 out of 5 starsMedical Sector531st out of 910 stocksPharmaceutical Preparations Industry243rd out of 426 stocks 4.4 Analyst's Opinion Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 14 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArvinas has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arvinas' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.46% of the outstanding shares of Arvinas have been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 13.9, which indicates bearish sentiment.Change versus previous monthShort interest in Arvinas has recently increased by 11.37%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARVN. Previous Next 3.0 News and Social Media Coverage News SentimentArvinas has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Arvinas this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows4 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.23% of the stock of Arvinas is held by insiders.Percentage Held by Institutions95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arvinas' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arvinas are expected to decrease in the coming year, from ($3.51) to ($4.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 2.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arvinas' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Arvinas Stock (NASDAQ:ARVN)Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Read More ARVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARVN Stock News HeadlinesSeptember 5 at 5:43 PM | msn.comArvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right NowAugust 29, 2024 | globenewswire.comArvinas to Participate in Upcoming Investor ConferencesSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 28, 2024 | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Receives $58.33 Consensus PT from AnalystsAugust 18, 2024 | finance.yahoo.comARVN Sep 2024 40.000 call (ARVN240920C00040000)August 5, 2024 | finance.yahoo.comBrokers Are Upgrading Their Views On Arvinas, Inc. (NASDAQ:ARVN) With These New ForecastsAugust 2, 2024 | finance.yahoo.comArvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesAugust 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arvinas Amidst Promising Clinical Trials and Strong Financial OutlookSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 2, 2024 | markets.businessinsider.comArvinas Holding Company (ARVN) Receives a Buy from Stifel NicolausJuly 31, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Arvinas Holding Company (ARVN)July 31, 2024 | benzinga.comArvinas (NASDAQ:ARVN) Stock Quotes, Forecast and News SummaryJuly 31, 2024 | benzinga.comThe Latest Analyst Ratings For ArvinasJuly 30, 2024 | finance.yahoo.comArvinas Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateJuly 26, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)July 12, 2024 | seekingalpha.comArvinas: Hugely Important Data Catalyst Upcoming - Success May Prove ElusiveJune 24, 2024 | globenewswire.comArvinas Appoints Andrew Saik as Chief Financial Officer and TreasurerJune 21, 2024 | globenewswire.comArvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2See More Headlines Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARVN CUSIPN/A CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees420Year FoundedN/APrice Target and Rating Average Stock Price Target$57.50 High Stock Price Target$90.00 Low Stock Price Target$20.00 Potential Upside/Downside+135.7%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-367,300,000.00 Net MarginsN/A Pretax Margin-344.48% Return on Equity-55.59% Return on Assets-26.64% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$93.30 million Price / Sales17.90 Cash FlowN/A Price / Cash FlowN/A Book Value$8.74 per share Price / Book2.79Miscellaneous Outstanding Shares68,432,000Free Float64,853,000Market Cap$1.67 billion OptionableOptionable Beta1.97 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. John G. Houston Ph.D. (Age 64)Chairperson, CEO & President Comp: $1.08MDr. Ian Taylor Ph.D. (Age 61)Chief Scientific Officer Comp: $692kDr. Randy Teel Ph.D. (Age 44)Interim CFO & Treasurer Mr. David K. Loomis M.B.A. (Age 50)VP, Principal Accounting Officer & Chief Accounting Officer Mr. Jeff BoyleVice President of Investor RelationsMr. Jared M. Freedberg J.D. (Age 55)General Counsel & Corporate Secretary Mr. Steve Weiss (Age 54)Senior VP & Chief Human Resources Officer Dr. John A. Grosso Ph.D. (Age 67)Senior Vice President of R&D Technical Operations Ms. Angela M. Cacace Ph.D. (Age 56)Senior Vice President of Neuroscience & Platform Biology Mr. John P. Northcott (Age 46)Chief Commercial Officer More ExecutivesKey CompetitorsSyndax PharmaceuticalsNASDAQ:SNDXPliant TherapeuticsNASDAQ:PLRXAnnexonNASDAQ:ANNXEnanta PharmaceuticalsNASDAQ:ENTAViking TherapeuticsNASDAQ:VKTXView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 208,854 shares on 8/16/2024Ownership: 1.502%Algert Global LLCSold 3,747 shares on 8/16/2024Ownership: 0.065%Millennium Management LLCSold 43,468 shares on 8/15/2024Ownership: 0.293%The Manufacturers Life Insurance Company Sold 24,376 shares on 8/15/2024Ownership: 0.139%ProShare Advisors LLCSold 2,852 shares on 8/14/2024Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions ARVN Stock Analysis - Frequently Asked Questions How have ARVN shares performed this year? Arvinas' stock was trading at $41.16 on January 1st, 2024. Since then, ARVN stock has decreased by 40.7% and is now trading at $24.40. View the best growth stocks for 2024 here. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings results on Tuesday, July, 30th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($1.08) by $0.59. The business's revenue was up 40.4% compared to the same quarter last year. When did Arvinas IPO? Arvinas (ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO. Who are Arvinas' major shareholders? Arvinas' top institutional investors include Perceptive Advisors LLC (1.50%), Candriam S.C.A. (0.89%), Dimensional Fund Advisors LP (0.68%) and Renaissance Technologies LLC (0.40%). Insiders that own company stock include John G Houston, Sean A Cassidy, Ian Taylor, Ronald Peck, Briggs Morrison, Liam Ratcliffe and Timothy M Shannon. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK) and Advanced Micro Devices (AMD). This page (NASDAQ:ARVN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
